RATIONALE: Chronic social defeat stress (CSDS) has been proposed as a model of depression. However, most CSDS studies rely only on the analysis of stress-induced social avoidance. Moreover, the predictive validity of the model has been poorly analyzed, let alone its interaction with biological risk factors. OBJECTIVES: Here, we explore the validity of CSDS as a depression model. Further, the effect of decreased vesicular glutamate transporter 1 (VGLUT1), as a potential factor enhancing a depressive-like phenotype, was studied. METHODS: Mice were exposed to CSDS (10 days) followed by saline, venlafaxine, fluoxetine, or tianeptine treatment (30 days). The battery of behaviors included motor activity, memory, anxiety, social interaction, helplessness, and anhedonic-like behavior. Moreover, the behavioral effect of CSDS in VGLUT1 heterozygous (VGLUT1+/-) mice was studied, as well as the regulation of VGLUT1 mRNA. RESULTS: CSDS induced anhedonia, helplessness, hyperactivity, anxiety, social avoidance, and freezing, as well as downregulation of VGLUT1 mRNA in the amygdala. Repeated venlafaxine showed antidepressant-like activity and both venlafaxine and tianeptine behaved as effective anxiolytics. CSDS-induced social avoidance was reverted by tianeptine. Fluoxetine failed to revert most of the behavioral alterations. VGLUT1+/- mice showed an enhanced vulnerability to stress-induced social avoidance. CONCLUSION: We suggest that CSDS is not a pure model of depression. Indeed, it addresses relevant aspects of anxiety-related disorders. Firstly, CSDS-induced anhedonia and social avoidance are not associated in this model. Moreover, CSDS might be affecting brain areas mainly involved in the processing of social behavior, such as the amygdala, where the glutamatergic mechanism could play a key role.
RATIONALE: Chronic social defeat stress (CSDS) has been proposed as a model of depression. However, most CSDS studies rely only on the analysis of stress-induced social avoidance. Moreover, the predictive validity of the model has been poorly analyzed, let alone its interaction with biological risk factors. OBJECTIVES: Here, we explore the validity of CSDS as a depression model. Further, the effect of decreased vesicular glutamate transporter 1 (VGLUT1), as a potential factor enhancing a depressive-like phenotype, was studied. METHODS:Mice were exposed to CSDS (10 days) followed by saline, venlafaxine, fluoxetine, or tianeptine treatment (30 days). The battery of behaviors included motor activity, memory, anxiety, social interaction, helplessness, and anhedonic-like behavior. Moreover, the behavioral effect of CSDS in VGLUT1 heterozygous (VGLUT1+/-) mice was studied, as well as the regulation of VGLUT1 mRNA. RESULTS: CSDS induced anhedonia, helplessness, hyperactivity, anxiety, social avoidance, and freezing, as well as downregulation of VGLUT1 mRNA in the amygdala. Repeated venlafaxine showed antidepressant-like activity and both venlafaxine and tianeptine behaved as effective anxiolytics. CSDS-induced social avoidance was reverted by tianeptine. Fluoxetine failed to revert most of the behavioral alterations. VGLUT1+/- mice showed an enhanced vulnerability to stress-induced social avoidance. CONCLUSION: We suggest that CSDS is not a pure model of depression. Indeed, it addresses relevant aspects of anxiety-related disorders. Firstly, CSDS-induced anhedonia and social avoidance are not associated in this model. Moreover, CSDS might be affecting brain areas mainly involved in the processing of social behavior, such as the amygdala, where the glutamatergic mechanism could play a key role.
Authors: Henrik Kessler; Julia Roth; Joern von Wietersheim; Russell M Deighton; Harald C Traue Journal: Depress Anxiety Date: 2007 Impact factor: 6.505
Authors: Iu A Aleksandrovskiĭ; A S Avedisova; I V Boev; A O Bukhanovkskiĭ; V M Voloshin; B D Tsygankov; B K Shamreĭ Journal: Zh Nevrol Psikhiatr Im S S Korsakova Date: 2005
Authors: Raffaella Molteni; Francesca Calabrese; Paola F Maj; Jocelien D A Olivier; Giorgio Racagni; Bart A Ellenbroek; Marco A Riva Journal: Eur Neuropsychopharmacol Date: 2009-07-03 Impact factor: 4.600
Authors: Michael Lutter; Ichiro Sakata; Sherri Osborne-Lawrence; Sherry A Rovinsky; Jason G Anderson; Saendy Jung; Shari Birnbaum; Masashi Yanagisawa; Joel K Elmquist; Eric J Nestler; Jeffrey M Zigman Journal: Nat Neurosci Date: 2008-06-15 Impact factor: 24.884
Authors: Klaus V Wagner; Daria Marinescu; Jakob Hartmann; Xiao-Dong Wang; Christiana Labermaier; Sebastian H Scharf; Claudia Liebl; Manfred Uhr; Florian Holsboer; Marianne B Müller; Mathias V Schmidt Journal: Neuropsychopharmacology Date: 2012-08-08 Impact factor: 7.853
Authors: Andre Der-Avakian; Manoranjan S D'Souza; David N Potter; Elena H Chartoff; William A Carlezon; Diego A Pizzagalli; Athina Markou Journal: Psychopharmacology (Berl) Date: 2017-03-09 Impact factor: 4.530